Zymeworks (ZYME) EBITDA (2021 - 2026)

Zymeworks has disclosed EBITDA across 6 years of filings, most recently posting -$44.6 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$44.6 million, down 102.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$102.8 million (up 8.5% YoY), and the FY2025 annual result was -$80.3 million, up 34.77% from the prior year.
• EBITDA came in at -$44.6 million for Q1 2026 at Zymeworks, down from -$41.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $309.4 million in Q4 2022 to a low of -$72.6 million in Q1 2022.
• The 5-year median for EBITDA is -$29.2 million (2023), against an average of -$14.2 million.
• Across the five-year window, EBITDA surged 890.33% in 2022 and sank 104.13% in 2023, its largest moves.
• Zymeworks' EBITDA stood at $309.4 million in 2022, then tumbled by 104.13% to -$12.8 million in 2023, then tumbled by 91.28% to -$24.5 million in 2024, then tumbled by 68.6% to -$41.2 million in 2025, then declined by 8.27% to -$44.6 million in 2026.
• The last three EBITDA figures came in at -$44.6 million (Q1 2026), -$41.2 million (Q4 2025), and -$19.3 million (Q3 2025), per Business Quant data.